IP Library › Granted Patent US 11,305,041
Granted Patent B2
US 11,305,041 · App. 16/920,877 · Granted Apr 19, 2022

Oxygenator antithrombotic coating and method of manufacture

Inventors: Takayuki Kido (Kanagawa, JP); Takao Anzai (Kanagawa, JP)
Assignee: Terumo Kabushiki Kaisha
A61M1/1625A61M1/1645A61M1/1698A61M1/3673B01D63/04B01D67/0088B01D71/40A61M2202/0225A61M2207/10B01D2325/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,305,041
App. No.
16/920,877
Granted
Apr 19, 2022
Kind
B2
Abstract

Hollow fiber membranes in an oxygenator for an extracorporeal blood circulator are coated with an antithrombotic polymeric material. The porous hollow fiber membranes for gas exchange have outer surfaces, inner surfaces forming lumens, opening portions through which the outer surfaces communicate with the inner surfaces in a housing. A blood flow path is outside of the hollow fiber membrane bundle in the housing, between a blood inlet port and a blood outlet port. The coating is obtained by filling the blood flow path with a colloidal solution containing an antithrombotic polymeric compound, and moving the colloid solution between the blood inlet port and the blood outlet port for a time that coats a predetermined amount of antithrombotic polymeric compound on the outer surfaces of the hollow fiber membranes. Other surfaces within the oxygenator contacting the blood flow likewise receive the coating.

Claims (11)

1. A method for manufacturing an oxygenator having a housing retaining a hollow fiber membrane bundle, wherein the hollow fiber membrane bundle comprises a plurality of porous hollow fiber membranes for gas exchange which have outer surfaces, inner surfaces forming lumens, and opening portions through which the outer surfaces communicate with the inner surfaces, wherein the oxygenator defines a blood flow path which is outside of the hollow fiber membranes in the housing between a blood inlet port and a blood outlet port, the method comprising:

filling the blood flow path with a colloidal solution containing an antithrombotic polymeric compound; and

moving the colloidal solution along the blood flow path between the blood inlet port and the blood outlet port for a time that coats a predetermined amount of antithrombotic polymeric compound on the outer surfaces of the hollow fiber membranes;

wherein the lumens of the hollow fiber membranes are used as a gas flow path, and carbon dioxide gas is passed through the gas flow path while moving the colloidal solution between the blood inlet port and the blood outlet port.

2. The method for manufacturing an oxygenator according to claim 1 , wherein the colloidal solution is moved alternately back and forth between the blood inlet port and the blood outlet port.

3. The method for manufacturing an oxygenator according to claim 1 , wherein the colloidal solution is circulated by a pump coupled to the blood inlet port and the blood outlet port.

4. The method for manufacturing an oxygenator according to claim 1 , wherein a flow rate of the carbon dioxide gas is 0.5 L/min·m 2 or more and 20 L/min·m 2 or less with respect to a membrane area (m 2 ) of a hollow fiber membrane.

5. The method for manufacturing an oxygenator according to claim 1 , wherein the colloidal solution contains 0.01% by mass or more of an antithrombotic polymeric compound.

6. The method for manufacturing an oxygenator according to claim 1 , wherein the antithrombotic polymeric compound has a structural unit derived from alkoxyalkyl(meth)acrylate represented by the following Formula (I):

wherein R 3 represents a hydrogen atom or a methyl group, R 1 represents an alkylene group having 1 to 4 carbon atoms, and R 2 represents an alkyl group having 1 to 4 carbon atoms.

7. The method for manufacturing an oxygenator according to claim 1 , wherein a weight average molecular weight of the antithrombotic polymeric compound is more than 200,000 and less than 800,000.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2020
From: KIDO, TAKAYUKI; ANZAI, TAKAO
To: TERUMO KABUSHIKI KAISHA
Reel/Frame 053123/0205 →
Priority Claims (1)
JP JP2018-001806 · Jan 10, 2018 · national
Continuity (2)
Continuation PCTJP2019000545 · Jan 10, 2019
Related Publication 20200330669A1 · Oct 22, 2020